Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer

Ephrin type-A receptor 2 (EphA2) is a member of the tyrosine receptor kinases, a family of membrane proteins recognized as potential anticancer targets. EphA2 highly expressed in a variety of human cancers, playing roles in proliferation, migration, and invasion. However, whether and how EphA2 regulates basal-like breast cancer (BLBC) cell stemness and chemoresistance has not been revealed. Here, KLF5 was proven to be a direct transcription factor for EphA2 in BLBC cells, and its expression was positively correlated in clinical samples from breast cancer patients. The inflammatory factor TNF-α could promote BLBC cell stemness partially by activating the KLF5-EphA2 axis. Moreover, phosphorylation of EphA2 at S897 (EphA2 pS897) induced by TNF-α and PTX/DDP contributes to chemoresistance of BLBC. Furthermore, the EphA2 inhibitor ALW-II-41-27 could effectively reduce EphA2 pS897 and tumor cell stemness in vitro and significantly enhance the sensitivity of xenografts to the chemotherapeutic drugs PTX and DDP in vivo. Clinically, tumor samples from breast patients with less response to neoadjuvant chemotherapy showed a high level of EphA2 pS897 expression. In conclusion, KLF5-EphA2 promotes stemness and drug resistance in BLBC and could be a potential target for the treatment of BLBC.

 

Comments：

The passage describes a study that investigates the role of EphA2 in regulating stemness and chemoresistance in basal-like breast cancer (BLBC) cells. The authors found that KLF5 is a transcription factor for EphA2, and its expression is positively correlated in clinical samples from breast cancer patients. TNF-α, an inflammatory factor, was shown to promote BLBC cell stemness by activating the KLF5-EphA2 axis. Additionally, phosphorylation of EphA2 at S897 induced by TNF-α and chemotherapeutic drugs PTX/DDP contributes to chemoresistance of BLBC. The authors further demonstrate that the EphA2 inhibitor ALW-II-41-27 can reduce EphA2 pS897 and tumor cell stemness in vitro and enhance the sensitivity of xenografts to PTX and DDP in vivo. Finally, the study showed that high expression of EphA2 pS897 is associated with less response to neoadjuvant chemotherapy in breast cancer patients.

Overall, the study provides evidence for the role of KLF5-EphA2 axis in promoting stemness and drug resistance in BLBC, suggesting that targeting EphA2 may have therapeutic potential for BLBC treatment.

Related Products

Cat.No.	Product Name	Information
S6515	ALW II-41-27	ALW II-41-27 (compound 7) is a potent inhibitor of Eph receptor tyrosine kinase with Kd of 12 nM for EphA2.

Related Targets

Ephrin receptor